DEVYSER DIAGNOSTICS AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 99 SEK | +5.77% |
|
-0.40% | +25.95% |
| Apr. 25 | Devyser Receives IVDR Approval for Post-Transplant Monitoring Software | CI |
| Apr. 23 | Devyser Diagnostics AB Enters into Co-Marketing Agreement with Hamilton Bonaduz AG | CI |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 1,346 | 1,152 | 1,280 | 1,524 | - | - |
| Enterprise Value (EV) 2 | 981 | 810.1 | 1,092 | 1,313 | 1,337 | 1,524 |
| P/E ratio | -49.7 x | -24.7 x | -23.9 x | -409 x | 39 x | 18 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 14.4 x | 9.1 x | 7.56 x | 6.1 x | 4.45 x | 4.11 x |
| EV / Revenue | 10.5 x | 6.4 x | 6.45 x | 5.26 x | 3.91 x | 4.11 x |
| EV / EBITDA | -64.5 x | -18.7 x | -23.8 x | 127 x | 21.7 x | 15.6 x |
| EV / FCF | -53 x | -12.6 x | -10.7 x | -164 x | 89.2 x | 17.7 x |
| FCF Yield | -1.89% | -7.95% | -9.32% | -0.61% | 1.12% | 5.64% |
| Price to Book | 3.37 x | 2.66 x | 3.35 x | 3.66 x | 3.16 x | - |
| Nbr of stocks (in thousands) | 15,188 | 16,006 | 16,284 | 16,284 | - | - |
| Reference price 3 | 64.41 | 48.08 | 52.71 | 59.91 | 59.91 | 59.91 |
| Announcement Date | 2/24/22 | 2/21/23 | 2/20/24 | - | - | - |
1DKK in Million2SEK in Million3DKK
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | - | 93.5 | 126.6 | 169.3 | 249.8 | 342.3 | 371.1 |
| EBITDA 1 | - | -15.2 | -43.4 | -45.8 | 10.35 | 61.74 | 98 |
| EBIT 1 | - | -21.2 | -52 | -58.9 | -1.315 | 45.69 | 76.1 |
| Operating Margin | - | -22.67% | -41.07% | -34.79% | -0.53% | 13.35% | 20.51% |
| Earnings before Tax (EBT) 1 | - | -21.9 | -52.7 | -54.4 | -0.415 | 45.64 | 71 |
| Net income 1 | -10.91 | -20.7 | -46 | -53.6 | -3.355 | 37.58 | 86 |
| Net margin | - | -22.14% | -36.33% | -31.66% | -1.34% | 10.98% | 23.17% |
| EPS 2 | -0.000920 | -1.297 | -1.949 | -2.205 | -0.1465 | 1.536 | 3.330 |
| Free Cash Flow 1 | - | -18.5 | -64.4 | -101.7 | -8 | 15 | 86 |
| FCF margin | - | -19.79% | -50.87% | -60.07% | -3.2% | 4.38% | 23.17% |
| FCF Conversion (EBITDA) | - | - | - | - | - | 24.3% | 87.76% |
| FCF Conversion (Net income) | - | - | - | - | - | 39.91% | 100% |
| Dividend per Share 2 | - | - | - | - | - | - | - |
| Announcement Date | 5/11/21 | 2/24/22 | 2/21/23 | 2/20/24 | - | - | - |
1SEK in Million2DKK
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 24.5 | 30.4 | 30.9 | 31.2 | 34.2 | 39.5 | 37.7 | 46.7 | 45.4 | 49.6 | 53.2 | 58.5 | 62.5 |
| EBITDA | - | - | - | - | - | -16.3 | -11.1 | -4.1 | -14.2 | - | - | - | - |
| EBIT 1 | -13.9 | -5.2 | -12.6 | -8.2 | -25.9 | -19.1 | -13.5 | -7.8 | -18.5 | -13.5 | -6.9 | -3.2 | -0.5 |
| Operating Margin | -56.73% | -17.11% | -40.78% | -26.28% | -75.73% | -48.35% | -35.81% | -16.7% | -40.75% | -27.22% | -12.97% | -5.47% | -0.8% |
| Earnings before Tax (EBT) | - | - | - | - | - | -19.3 | -13.8 | -5.2 | -16.2 | - | - | - | - |
| Net income | - | - | - | - | - | -19.9 | -14.6 | -6 | -13.1 | - | - | - | - |
| Net margin | - | - | - | - | - | -50.38% | -38.73% | -12.85% | -28.85% | - | - | - | - |
| EPS | - | - | - | - | - | -0.8259 | -0.5650 | -0.2366 | -0.5328 | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 2/24/22 | 5/11/22 | 8/24/22 | 11/10/22 | 2/21/23 | 5/9/23 | 8/23/23 | 11/9/23 | 2/20/24 | - | - | - | - |
1SEK in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - |
| Net Cash position 1 | - | 365 | 342 | 188 | 211 | 187 | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow 1 | - | -18.5 | -64.4 | -102 | -8 | 15 | 86 |
| ROE (net income / shareholders' equity) | - | -7.79% | -10.8% | -13.1% | -0.81% | 8.89% | 21% |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - |
| Book Value Per Share 2 | - | 19.10 | 18.10 | 15.80 | 16.40 | 19.00 | - |
| Cash Flow per Share | - | - | - | - | - | - | - |
| Capex 1 | - | 2.2 | 7.9 | 11.5 | 8.78 | 8.76 | 13 |
| Capex / Sales | - | 2.35% | 6.24% | 6.79% | 3.51% | 2.56% | 3.5% |
| Announcement Date | 5/11/21 | 2/24/22 | 2/21/23 | 2/20/24 | - | - | - |
1SEK in Million2DKK
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
59.91
DKK
Average target price
80.73
DKK
Spread / Average Target
+34.75%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +25.95% | 141M | |
| +21.74% | 46.4B | |
| -0.97% | 41.75B | |
| +49.39% | 41.37B | |
| -3.52% | 29.71B | |
| +11.12% | 26.01B | |
| -19.37% | 19.52B | |
| +31.18% | 12.43B | |
| -0.04% | 12.13B | |
| +0.39% | 12.18B |
- Stock Market
- Equities
- DVYSR Stock
- Financials Devyser Diagnostics AB